All News

Article

EULAR 2021 - Day 2 Podcasts

Jack Cush, MD

Check out this compilation of our EULAR 2021 Day 2 broadcasts below.



You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.com



Listen by Clicking below:

Robert B Chao, MD Tweet
doctorRBC
Excellent talk on SLE, APS abs pregancy ⭐️pregnancy counseling is important ⭐️aspirin 81mg in all pregnant SLE pts ⭐️do not discontinue HCQ ⭐️stable LN - can switch MMF to AZA Abs#6888 #EULAR2021 @RheumNow
David Liew Tweet
drdavidliew
On choosing an agent for MTX-IR RA: "(at the end of talk) My short answer could have been... there's no right or wrong. It's still one of the dilemmas we have in the treatment of RA: choosing the right drug for the right patient" - @DanielAletaha #EULAR2021 @RheumNow https://t.co/C45ey1SrA1
Paul Studenic Tweet
Stiddyo
@DanielAletaha @RheumNow In the end the best treatment choice after #MTX insufficient responders not yet clear. Head to head JAK-i vs. non-TNFi interesting Brilliant developing discussion number needed to harm vs. number needed to treat #EULAR2021 @RheumNow
Jeffrey Sparks MD MMSc Tweet
jeffsparks
Results: MTX vs. PBO ✅Difference in least-squares mean ΔeGFR 0.93 mL/min/1.73m2 (p<0.001) ✅HR for kidney AE on safety labs: 0.73 (0.59-0.91) ✔️HR for kidney AE clinical events: 0.87 (0.56-1.36) ✔️4 vs. 8 severe kidney AEs (HR 0.50, 0.15-1.64)
Jeffrey Sparks MD MMSc Tweet
jeffsparks
🤜MTX safe from kidney perspective if baseline CrCl 40+ 🤜Potential for immunomodulation to prevent/slow progression to CKD? Deserves dedicated studies @Nephro_Sparks
Md Yuzaiful Md Yusof Tweet
Yuz6Yusof
Which biomarkers could guide csDMARDs tapering in #RA patients in #remission? Dr Gul reported in a cohort study using a tapering protocol, 35% had relapsed. Risk score for sustained remission comprise IRC<2%, MSK-US PD=0 and RAQoL=<1 (AUC=0.89) #EULAR2021 #OP0182 @RheumNow https://t.co/y1Y6ug7f3w
Eric Dein Tweet
ejdein1
PS0103 #EULAR2021. Do you adjust complement levels by time of pregnancy? ⭐️Mean C3 ⬆️28% compared to 1st trimester ⭐️Mean C4 ⬆️ 11% compared to 1st trimester @RheumNow
Eric Dein Tweet
ejdein1
#EULAR LB0003 Pfizer #COVID vax immunogenicity and safety in 686 rheum pts in Israel ⭐️Sero+ for COVID Ab 86% in RMD vs 100% controls ⭐️RTX lowest seropos of 39%, related to time of infusion ⭐️⬇️ with GC, ABA, MMF ⭐️ MTX not seen to significantly ⬇️ @RheumNow @rheum_covid
k dao Tweet
KDAO2011
#POS0022 prosp study of CTZ pregnancies: 1392 preg w/1425 outcomes @UCBUSA database 88.4% live births, 10.5% preg loss, 0.8% still birth 2.4% congen malform (w/2.1% major) Preg loss⬅️Crohn's, NSAIDS, MTX Preterm labor⬅️GCs, maternal infx ⬇️birth wt⬅️RA & GCs @rheumnow #EULAR2021 https://t.co/qnNcDIz8Ge
Aurelie Najm Tweet
AurelieRheumo
Serious infections and BioDMARDs: what is the confounding factor? BSRBR-RA: 33,916 RA treated w/ BioDMARDs with 62,532 years of follow-up, 2036 SI. HR of SI no longer different among BioDMARDs when adjusted for the line of therapy! #OP0241@Rheumnow #EULAR2021 https://t.co/UG9WrXP7RD
Meral K. El Ramahi, MD Tweet
MeralElRamahiMD
2021 GRAPPA STRONG recs (cont'd): *⃣Crohn's Dz & UC: TNFi (not ETN), IL12/23i 🚫strong rec against IL17i 2021 GRAPPA CONDITIONAL recs for: *⃣ Uveitis: TNFi (not ETN), CyA *⃣ Crohn's Dz & UC: IL23i, JAKi, MTX OP0229 #EULAR2021 @RheumNow https://t.co/AWyKqSapWG
Robert B Chao, MD Tweet
doctorRBC
Lower ILD incidence in PsA than RA in a large Nordic registry ⭐️ No significant ⬆️ in ILD in those using MTX Abs#OP0222 #EULAR2021 @RheumNow https://t.co/lgGhu1Hmd6
Paul Studenic Tweet
Stiddyo
#OP0228 Phase 3 RCT on Risankizumab - KEEPsAKE 2 -PsA with 49% prior bDMARD 95% prior csDMARD: week 24 results PE: ACR20 51% active vs 26% on PLC PASI90: 55% active vs. 10% PLC #EULAR2021 @RheumNow https://t.co/UkZLcXTNnq
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×